Drug delivery strategies for paediatric diffuse midline gliomas.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Diffuse midline gliomas (DMGs) are a highly aggressive and inoperable type of paediatric brain tumours, with a median survival of less than one year. Therapeutic progress has been hindered by the tumour's anatomical location, its extensive molecular heterogeneity, and the restrictive nature of the blood brain barrier (BBB) in drug delivery. This article explores the current therapeutic landscape of DMG and evaluates emerging drug delivery strategies, including oral, intravenous and intrathecal administration, convection-enhanced delivery (CED), and intranasal approaches, designed to improve drug access to the brain. Advancements in these methods, combined with targeted therapies tailored to the tumour's unique molecular features, represent a critical pathway towards improving clinical outcomes for DMG patients.